Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B

Fitusiran is a first-in-class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor-independent prophylaxis. This commentary aims to summarize the clinical evidence supporting fitusiran, highlight its therapeutic significance, and discuss its potential advantages and safety considerations.

This commentary reviews key findings from Phase 1-3 clinical trials, including ATLAS-INH and ATLAS-PPX, as well as regulatory documents and published pharmacologic evaluations. Evidence on annualized bleeding rate (ABR) reduction, thrombin generation, safety outcomes, and patient-reported benefits was synthesized to assess the impact of AT suppression on bleed prevention.

Across clinical development, fitusiran produced substantial reductions in bleeding rates in Hemophilia A and B, irrespective of inhibitor status. Phase 1 and 2 trials demonstrated > 70%-80% AT suppression with marked increases in thrombin generation. In Phase 3 trials, median ABR decreased from 17.7 to 0.0 in ATLAS-INH and by approximately 65% in ATLAS-PPX after switching from standard prophylaxis. Many participants remained completely bleed-free. Safety findings included reversible elevations in liver enzymes, mild injection-site reactions, headaches, and rare thrombotic events, necessitating AT-level and hepatic monitoring.

Fitusiran offers a transformative, once-monthly prophylactic option with broad applicability across hemophilia types and inhibitor status. Its RNAi-based, factor-independent mechanism enables durable bleed protection and improved treatment convenience. While long-term hepatic safety and thrombotic risk require continued surveillance, fitusiran represents a significant advance in hemophilia management and a promising step toward more accessible, individualized, and rebalancing-based therapies.